ESMO AI at a glance
Get ready for ESMO AI and Digital Oncology 2025 with LucidQuest’s concise preview—spotlighting must-see sessions and emerging themes in AI-driven oncology.
📅 Build your schedule around the topics that interest you. 📥 Download the ESMO -AI 2025_Preview_by_LucidQuest.
Dive deeper
Key Topics From Notable Presentations on Artificial Intelligence & Machine Learning
AI for Treatment Response, Immunotherapy & Precision Oncology
- AI biomarkers and digital pathology set to personalize therapy selection and predict response across major tumor types.
Personalized Biomarkers & Predictive Models
- Multi-omic profiling in NSCLC, TNBC, melanoma identifies pTLS and immune signatures, enabling immunotherapy and ADC selection.
AI in Prognosis & Survival Prediction
- SVM and XGBoost forecast overall survival and long-term outcomes in mNSCLC, CRC, aHCC, supporting risk stratification and tailored follow-up.
Innovative AI for Diagnosis & Scheduling
- Early NSCLC detection and circadian ICI timing tools aim to optimize workflows and improve therapeutic efficacy.
AI-Driven Oncology Decision Support
- ClioAssist and Konsuld® set to automate workflows, provide real-time decision support, and enable global peer consultations.
Digital Health, Patient Monitoring & ePROs
- AI tools, wearables, and integrated ePRO platforms enable real-time symptom tracking, streamline workflows, and improve quality of life.
Radiomics & Imaging AI
- Radiomics predicts EGFR mutations, HER2 status, and glioma subgroups, offering noninvasive biomarkers to guide precision treatment.
Breast Recurrence Risk Prediction
- Deep learning on histopathology + clinical data achieved AUC 0.898, reclassifying high-risk patients and reducing unnecessary chemotherapy.
MSI Detection in Gastric Cancer
- Equivariant Neural Field reached AUC 70.0 on biopsies, outperforming baselines while reducing computational complexity.
Trial Matching for Lung Cancer
- LungTrial-LLMX achieved 83% patient–trial matching accuracy using a privacy-preserving dual-LLM design with transparent reasoning.
LLMs for MDT Decisions
- Initial concordance 67.2% for MDT use; ChatGPT-5 reached 75.7% for breast adjuvant recommendations, expanding discussion breadth and options.
📅 Build your schedule around the topics that interest you.
📥 Download the ESMO -AI 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.